Could not follow all the talks (it's really exhausting) but here's my short impression of the NIH conference:
There were some bad things. The online feed kept falling out, some presentations hardly said a word about ME/CFS and there were a lot of empty chairs. The people that were there and were asking most of the questions were either presenters or patients/carers. There doesn't seem to be a lot of interest from outside the field. Collins talked about how wonderful the NIH is, not about plans to further the ME/CFS field.
The talks on immunology and the microbiome showed that the research being done is really complex and that all sorts of fancy techniques are being used to study ME/CFS. That's hopeful but on the other hand, most of the findings were negative. If I remember correctly both the intramural and Lipkin study found no abnormalities in the NK-cells, The T-cell clonal expansion didn't work out and there isn't really a consistent finding that is being replicated by the different groups (except for TGF-beta, perhaps). The talks from Nancy Klimas, Jose Montoya, Jacksons Labs, and Cornell, were mostly about complex modeling. Unfortunately, I didn't have the feeling these researchers were on to something that could lead to a breakthrough in the near future. I like unexpected findings much more than complex modeling.
The talks on exercise tests were more interesting in that regard. Betsy Keller talked about chronotropic incompetence, the inability to increase the heart rate during exercise. Their review on this topic showed that many exercise test studies have reported this in ME/CFS patients. If I remember correctly Keller said her group had replicated this in a large cohort. She also reported that ME/CFS patients often show other abnormalities during exercises such as low ventilation or failure to increase blood pressure. To her, his all suggests autonomic dysfunction. Systrom seemed to agree with that, as he reported low filling pressure in ME/CFS patients - blood from veins not filling the heart as it should. This section of the talks was summed up by one of the persons asking questions. He said he was a researcher specialized in exercise intolerance and intrigued by the literature on ME/CFS. He claimed: "this is a cardiovascular disease until proven otherwise." Don't know if that is true, but the exercise researchers seemed to be on to something. Would be interesting if we had another research team like the Workwell Foundation, that tried to replicate their findings.
Then there were two interesting talks by the young researchers Younger and VanElzakker. Both are excellent speakers. They only had preliminary findings to report but seemed to have a lot of good research ideas regarding brain scans in ME/CFS. This seems like another promising field.
To me, the most intriguing finding came from the German researcher Bhupesh Prusty. His talk was about HH6 and the ability of this virus to disrupt mitochondria. He found that only a few ME/CFS cells were infected by the HH6 virus so this probably isn't the explanation. The interesting thing was that he reported reversible serum-induced mitochondrial alterations. In other words: there seems to be something in ME/CFS patients' serum that is changing the mitochondrial structure. And it's reversible, he said, if you wash it off, then the mitochondria turn normal again. Fluge et al. reported that there is something in the serum that affects mitochondrial function back in 2016. They wrote that "the cells exposed to ME/CFS serum displayed a metabolic change involving amplified lactate production under conditions of energetic strain." It's also similar to what Ronald Davis reported in his plasma swap experiment - if you put healthy cells in ME/CFS patients' serum, you get a signal on the nanoneedle device. But if you put a ME/CFS cel in healthy serum, there's no signal. This also suggests there is something in the serum. Davis said they don't think it's a metabolite or cytokine, but probably an exosome. He also said that it could very well be that the nanoneedle signal reflects changes in the mitochondrial structure.
There were some other interesting findings such as lower B-cells in the spinal fluid but not the blood, reported by the intramural NIH study. Ronald Davis tested the nanoneedle successfully in 10 more patients and has a paper accepted for this in the top journal PNAS. All in all, it was hopeful to see all these top scientists present their findings on ME/CFS.